Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRX34 in advanced melanoma
NCT02862145Phase 2Withdrawn
- Sponsor
- Mirna Therapeutics
- Start
- Aug 2016
- Primary completion
- Sep 2017
- Modality
- RNA Therapeutics
01
Overview
A Phase 2 trial of mir-34 in melanoma, sponsored by Mirna Therapeutics. Planned start Aug 2016; status: withdrawn.
02
Drugs
mir-34
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02862145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02862145.